MPayz Token Official Updates
151 subscribers
1 photo
2 files
12 links
Download Telegram
Channel photo updated
Channel name was changed to Β«MPayz Token Official UpdatesΒ»
MAPay and Trinidad and Tobago Collaboration πŸš€

MAPay and Invest TT is excited about a collaboration to increase healthcare access, reduce healthcare costs, improve efficiencies, and empower citizens with their healthcare data.

Here is a link to Invest TT to learn more about this amazing organization!

http://www.investt.co.tt/
❀16πŸ”₯10πŸ‘8πŸ’©2
Give our new Instagram post a like and a share!

https://www.instagram.com/tv/CgC9aTUs4kh/?igshid=YmMyMTA2M2Y=
πŸ‘23😱12❀10πŸ”₯8πŸ₯°8😁8🀩4
We are excited to announce a collaboration with Drexel University to deploy a transformational healthcare payment and data exchange network that uses Non-Fungible Tokens (NFT's) to democratize healthcare data using the innovative @algorand blockchain

https://blockchainreporter.net/drexel-university-college-of-medicine-and-healthcare-payments-innovator-mapay/
😱33πŸ‘13🀩13❀11😁9πŸ₯°8πŸ”₯4
Hello everyone, if you are on Twitter please join us on a Twitter Space hosted by W3BX with our CEO Michael Dershem!

https://twitter.com/web3expo/status/1567916963833298945?s=20&t=y7E9zjD2p4QPxF3bXM_Whw
πŸ‘35πŸ€”3
Some of you may be wondering why we selected Bermuda to domicile the company here's some insight to our line of thinking!


Why Bermuda? Bermuda has been selected to domicile the Company due to the Country’s recognition as a global leader in the regulation of businesses using blockchain and cryptocurrencies. The Bermuda government has pioneered one of the world's first comprehensive regulatory and legislative frameworks specifically designed to provide legal and regulatory certainty to industry participants whilst ensuring that business in the sector is conducted in accordance with the highest international standards.

Bermuda has developed a collaborative business culture that involves government and industry working together to create opportunity and commercial success with truly independent, actively engaged and globally recognized regulators maintaining the balance between the promotion of innovation and adherence to worldwide standards of regulation, compliance, and transparency. This collaborative business culture extends to this venture and Bermuda will also be one of the first adopters of MPayz.
πŸ‘98πŸ”₯10❀9πŸ‘4
Please Join Us This Thursday 9/29 at 5PM EST on the W3BX Twitter account to learn about new developments with MAPay and MPayz. Our CEO Michael Dershem, our Head of Development Mahesh Chand, and Chief Strategy Officer Bhaskar Das will be speaking!
 
https://twitter.com/i/spaces/1YpKkgXwBOXKj
πŸ‘28πŸ”₯10
DERSH.mp4
2.1 MB
Please Join Us Tomorrow 9/29 at 5PM EST on the W3BX Twitter account to learn about new developments with MAPay and MPayz. Our CEO Michael Dershem, our Head of Development Mahesh Chand, and Chief Strategy Officer Bhaskar Das will be speaking!
 
https://twitter.com/i/spaces/1DXGyvwdOELJM
πŸ‘10πŸ•Š3❀1
DERSH.mp4
2.1 MB
Don't miss the Twitter Space today at 5pm EST with our CEO Michael Dershem, our Head of Development Mahesh Chand, and Chief Strategy Officer Bhaskar Das will be speaking!

Click the link to listen in!

https://twitter.com/i/spaces/1DXGyvwdOELJM
😁6🀩5πŸ‘3πŸ‘2
Forwarded from J
We'd like to announce the the appointment of Basil Hantash to the MAPay/MPayz Advisory team!
πŸ”₯11πŸ₯°10🀩10❀9πŸŽ‰7πŸ‘5πŸ‘4😁3😱3
Forwarded from J
Bio:
Dr. Hantash is a serial entrepreneur who has successfully founded multiple healthcare companies. During the course of his career, Dr. Hantash has acquired or launched over a dozen life sciences products in medical devices, diagnostics, small molecule drugs, biomaterials, cosmeceuticals, nutraceuticals, cell therapy, and nanotechnology. In addition, he has served on the founding team of over 10 medical device and biotech start-ups, accumulating 18 years of operational experience including executive, BOD, SAB, and consultant roles. Dr. Hantash’s intellectual property has led to the development of several breakthrough medical devices and skin care products and his R&D efforts have led to the completion of 4 acquisitions, over a dozen FDA-approvals, >100 issued and pending patents, >165 scientific peer-reviewed articles, abstracts, and book chapters, and the creation of over $1B of shareholder value.
πŸŽ‰15πŸ₯°10πŸ”₯9❀7πŸ‘7😁6πŸ‘4🀩3
Forwarded from J
Dr. Hantash is a 30-year veteran of Regenerative Medicine, conducting pioneering research at Stanford University investigating the mechanisms underlying mesenchymal stem cell immune tolerance. In 2006, based on his Stanford intellectual property, Dr. Hantash founded and serves as Chairman, CEO, & CSO of Escape Therapeutics, a Stanford University spin out based in Silicon Valley focused on creating the world’s first universal, off-the-shelf, stem cell source for human clinical use.
πŸ‘13πŸ₯°11😁11πŸ”₯8🀩6❀1
Forwarded from J
Dr. Hantash started his Life Science career at Abbott Labs, where he developed and successfully launched a hepatitis screening assay. Dr. Hantash then joined Molecular Geriatrics, a neuroscience Biotech start-up founded by Nobel laureate Ferid Murad, MD, PhD. His work there contributed to the discovery and patenting of a novel therapeutic drug for Alzheimer’s disease that was sold to Upjohn. Dr. Hantash completed his Dermatology Residency, Postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from Rutgers University, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship. He completed his MBA with honors at The Wharton School, University of Pennsylvania, where he was awarded the Price Institute Fellowship for entrepreneurship. He remains intimately involved in humanitarian relief work and is an award-winning poet featured in several books and one audio CD.
😱39🀩24😁22πŸ‘19❀6πŸ₯°5πŸ”₯4πŸ‘4
😁39🀩38πŸ‘31πŸ‘20πŸ”₯18πŸ₯°17😱14❀12
If you are on Twitter please join us at 2pm EST today on the Algorand Twitter account for a Twitter Space with our CEO Michael Dershem!

https://twitter.com/i/spaces/1BdxYymdXlMxX?s=20
πŸ‘51😁37🀩36😱31πŸ₯°28πŸ”₯22❀19
FTX STATEMENT

We have received several inquiries about the impact of the FTX scandal on MAPay’s efforts to launch MPayz.   The collapse of FTX, which has followed an extended period of overall negative news and declining cryptocurrency token prices, has certainly not been a welcomed event for the overall industry.  The MPayz project has no connection to FTX or any other leveraged exchange. We have taken additional precautions in our selection of the exchanges we plan to partner with for the launch.
 
We believe, however, that the net effect of this period will ultimately prove to have been β€œhard now, better later”.  The substance of the MPayz project, and the benefits to the overall healthcare market, will only be further advanced.  Both MPayz and MAPay will emerge as positive examples of blockchain-based companies, both regulated and providing real tangible benefits.  We believe the current overall negativity in the wide umbrella referred to as the β€œcrypto industry” will only further enhance the achievements of MPayz and MAPay.
πŸ‘86🀩62😁59πŸ₯°44😱43❀30πŸ”₯4